ImmunityBio Reports Q1 Loss but Strong Anktiva Demand Persists
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy IBRX?
Source: stocktwits
- Financial Performance: ImmunityBio reported a Q1 net loss of $632.8 million, significantly up from $129.6 million a year ago, although revenue of $44.2 million slightly exceeded consensus estimates of $43.9 million, indicating financial strain on the company.
- Growing Anktiva Demand: Despite the increased losses, CEO Richard Adcock emphasized that demand for Anktiva continues to grow, particularly among new prescribers and in maintenance settings, suggesting the company's competitive position remains strong in the market.
- FDA Application Progress: ImmunityBio's resubmitted supplemental biologics license application is under FDA review, with data from the Quilt 3.032 study showing that 58.2% of patients remained cancer-free after 12 months, potentially supporting the company's future market performance.
- Investor Sentiment: On Stocktwits, retail investor sentiment for IBRX is deemed 'bullish', with many users expressing confidence in Anktiva and ImmunityBio's future developments, reflecting an optimistic outlook on the company's potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.760
Low
5.00
Averages
7.33
High
9.00
Current: 7.760
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Lawsuit Background: The lawsuit alleges that executives of ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the true information was revealed, highlighting misconduct within the company.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having secured hundreds of millions in settlements, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and influence in the field.
See More
ImmunityBio Shareholder Class Action Reminder
- Class Action Notice: Robbins LLP reminds all shareholders who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19, 2026, and March 25, 2026, that a class action has been filed to protect investor rights and seek compensation.
- False Statement Allegations: The complaint alleges that CEO Soon-Shiong materially overstated the capabilities of the company's lead biologic product, ANKTIVA, leading investors to misunderstand its potential effects.
- FDA Warning Letter Impact: On March 24, 2026, a warning letter from the U.S. Food and Drug Administration (FDA) indicated that Soon-Shiong's promotional claims misleadingly suggested that ANKTIVA could cure and prevent all cancers, resulting in a 21% drop in ImmunityBio's stock price to $7.42 per share on that day.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers to the court by May 26, 2026, while those who choose not to participate can remain absent class members and still retain their rights to recovery.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Announcement: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio (NASDAQ:IBRX) for investors who purchased shares between January 19 and March 24, 2026, highlighting significant investor concerns regarding the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially misleading statements during this period, particularly regarding the efficacy of its cancer vaccine Anktiva, which has severely undermined investor confidence in the company's prospects.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price to $7.42 per share, illustrating the direct impact of regulatory risks on the company's valuation.
- Investor Action Recommendations: Investors are advised to file for lead plaintiff status by May 26, 2026, to represent other investors in the class action, reflecting a strong emphasis on legal rights and expectations for improved corporate governance.
See More
ImmunityBio Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against ImmunityBio, seeking damages for investors who purchased securities between January 19 and March 24, 2026, highlighting concerns over potential financial losses among investors.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, rendering the company's statements about its business, operations, and prospects materially false and misleading, which could have long-term repercussions on the company's reputation and stock price.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by May 26, 2026, to participate in potential recovery, indicating a proactive stance among investors to protect their rights.
- Law Firm Background: Bronstein, Gewirtz & Grossman is recognized for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions, which may bolster investor confidence in the case.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to further losses for investors.
- Efficacy Claims Controversy: Soon-Shiong claimed in a podcast that Anktiva could treat all cancers, while the FDA stated that these promotional materials mislead the public and fail to provide complete information regarding Anktiva's FDA-approved indications, posing potential public health risks.
- Investor Rights Protection: Hagens Berman is urging investors who suffered significant losses to submit their information and is encouraging witnesses to assist in the investigation, demonstrating a commitment to protecting investor rights and pursuing corporate transparency.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiation: Purchasers of ImmunityBio, Inc. securities between January 19 and March 24, 2026, have until May 26, 2026, to seek lead plaintiff status in a class action lawsuit alleging violations of the Securities Exchange Act of 1934, potentially exposing investors to significant losses.
- False Statement Allegations: The lawsuit claims that ImmunityBio made false and misleading statements regarding its lead biologics product Anktiva, asserting it could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated, which may undermine investor confidence.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio's CEO, stating that promotional materials misbranded Anktiva, violating the Federal Food, Drug, and Cosmetic Act, leading to a 21% drop in stock price, directly impacting the company's financial health.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, demonstrating its significant strength and influence in securities class action lawsuits.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Lawsuit Background: The lawsuit alleges that executives of ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the true information was revealed, highlighting misconduct within the company.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having secured hundreds of millions in settlements, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and influence in the field.
See More
ImmunityBio Shareholder Class Action Reminder
- Class Action Notice: Robbins LLP reminds all shareholders who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19, 2026, and March 25, 2026, that a class action has been filed to protect investor rights and seek compensation.
- False Statement Allegations: The complaint alleges that CEO Soon-Shiong materially overstated the capabilities of the company's lead biologic product, ANKTIVA, leading investors to misunderstand its potential effects.
- FDA Warning Letter Impact: On March 24, 2026, a warning letter from the U.S. Food and Drug Administration (FDA) indicated that Soon-Shiong's promotional claims misleadingly suggested that ANKTIVA could cure and prevent all cancers, resulting in a 21% drop in ImmunityBio's stock price to $7.42 per share on that day.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers to the court by May 26, 2026, while those who choose not to participate can remain absent class members and still retain their rights to recovery.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Announcement: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio (NASDAQ:IBRX) for investors who purchased shares between January 19 and March 24, 2026, highlighting significant investor concerns regarding the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially misleading statements during this period, particularly regarding the efficacy of its cancer vaccine Anktiva, which has severely undermined investor confidence in the company's prospects.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price to $7.42 per share, illustrating the direct impact of regulatory risks on the company's valuation.
- Investor Action Recommendations: Investors are advised to file for lead plaintiff status by May 26, 2026, to represent other investors in the class action, reflecting a strong emphasis on legal rights and expectations for improved corporate governance.
See More
ImmunityBio Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against ImmunityBio, seeking damages for investors who purchased securities between January 19 and March 24, 2026, highlighting concerns over potential financial losses among investors.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, rendering the company's statements about its business, operations, and prospects materially false and misleading, which could have long-term repercussions on the company's reputation and stock price.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by May 26, 2026, to participate in potential recovery, indicating a proactive stance among investors to protect their rights.
- Law Firm Background: Bronstein, Gewirtz & Grossman is recognized for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions, which may bolster investor confidence in the case.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to further losses for investors.
- Efficacy Claims Controversy: Soon-Shiong claimed in a podcast that Anktiva could treat all cancers, while the FDA stated that these promotional materials mislead the public and fail to provide complete information regarding Anktiva's FDA-approved indications, posing potential public health risks.
- Investor Rights Protection: Hagens Berman is urging investors who suffered significant losses to submit their information and is encouraging witnesses to assist in the investigation, demonstrating a commitment to protecting investor rights and pursuing corporate transparency.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiation: Purchasers of ImmunityBio, Inc. securities between January 19 and March 24, 2026, have until May 26, 2026, to seek lead plaintiff status in a class action lawsuit alleging violations of the Securities Exchange Act of 1934, potentially exposing investors to significant losses.
- False Statement Allegations: The lawsuit claims that ImmunityBio made false and misleading statements regarding its lead biologics product Anktiva, asserting it could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated, which may undermine investor confidence.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio's CEO, stating that promotional materials misbranded Anktiva, violating the Federal Food, Drug, and Cosmetic Act, leading to a 21% drop in stock price, directly impacting the company's financial health.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, demonstrating its significant strength and influence in securities class action lawsuits.
See More
